犬の慢性心不全に対するマレイン酸エナラプリルの治療試験

DOI 日本農学文献記事索引 Web Site 被引用文献2件 参考文献13件

書誌事項

タイトル別名
  • Clinical Evaluation of Enalapril Maleate for Treatment of Heart Failure in Dogs.
  • イヌ ノ マンセイ シンフゼン ニ タイスル マレインサン エナラプリル ノ

この論文をさがす

抄録

A multi-center field study to assess the safety and efficacy of enalapril maleate (enalapril) in household dogs with naturally acquired Class III or Class IV heart failure caused mainly by mitral regurgitation was conducted at 20 animal hospitals in Japan. One hundred and thirty-six dogs of various breeds and each sex, aged 5 to 18 years and weighing 1.4 to 19.7 kg were included in the study and were randomly allocated to a vehicle control group (control group) or to an enalapril treatment group (enalapril group). Dogs in the enalapril group received the medication at the starting dose of approximately 0.25 mg/kg once a day (s.i.d.) for 7 days, followed by 0.5 mg/kg s.i.d., with an option to increase the dose on Day 14 to 0.5 mg/kg twice a day (b.i.d.) based on the results of physical examination and laboratory testing on Day 14. Dogs in the control group received vehicle tablets. Doses were administered for approximately 28 days. All but one dogs received standard therapy for congestive heart failure : 125 (92%) dogs received furosemide (maximum 4 mg/kg/day) and 125 (92%) dogs received digoxin (maximum 10μg/kg/day) at the discretion of the investigator. Sixtyseven and 69 dogs were allocated to the control group and the enalapril group, respectively. Forty-four (66%) dogs in the control group completed the study when compared to 57 (83%) dogs in the enalapril group. The improvement from baseline to Day 28 was significantly greater for dogs in the enalapril group than for those in the control group for all scored parameters: activity, mobility, appetite, coughing, respiratory effort, pulmonary edema, and class of heart failure. Overall evaluation judged by the investigators were significantly better for the enalapril-treated dogs than for the control dogs on Days 7, 14 and 28. No differences were observed between the enalapril group and the control group for changes in all laboratory testing parameters (serum chemistry, electrolytes, etc.). No adverse reactions attributable to enalapril treatment were observed. The results of the study demonstrate that enalapril administered at 0.25 to 0.5 mg/kg s.i.d. with standard therapy of heart failure improves the clinical signs associated with heart failure. There were no enalapril-related adverse reactions.

収録刊行物

被引用文献 (2)*注記

もっと見る

参考文献 (13)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ